Patents by Inventor Reimar ABRAHAM

Reimar ABRAHAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of anti-FGFR4-antibody and bile acid sequestrant
    Patent number: 11648310
    Abstract: The present invention relates to the amelioration of toxic effects that are caused by therapies aimed at FGFR4-inhibition. In particular, the invention relates to the combination of FGFR4 inhibitors and agents capable of reducing bile acid levels and to the use thereof in the treatment of diseases.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: May 16, 2023
    Inventors: Reimar Abraham, Mauricio Redondo-Müller
  • ANTI-HER3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20220172420
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Application
    Filed: February 10, 2022
    Publication date: June 2, 2022
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore HETTMANN, Reimar ABRAHAM, Sabine BLUM, Suguru UENO
  • Anti-HER3 antibody-drug conjugate
    Patent number: 11298359
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 12, 2022
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore Hettmann, Reimar Abraham, Sabine Blum, Suguru Ueno
  • Combination of human anti-FGFR4 antibody and Sorafenib
    Patent number: 10995143
    Abstract: The present invention relates to the medical use of antibodies against the FGF receptor 4 (FGFR4) combined with Sorafenib, in particular for the prevention or treatment of hyperproliferative diseases associated with FGFR expression, overexpression or hyperactivity.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: May 4, 2021
    Assignees: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Company Limited
    Inventors: Reimar Abraham, Keisuke Fukuchi
  • COMBINATION OF ANTI-FGFR4-ANTIBODY AND BILE ACID SEQUESTRANT
    Publication number: 20210023211
    Abstract: The present invention relates to the amelioration of toxic effects that are caused by therapies aimed at FGFR4-inhibition. In particular, the invention relates to the combination of FGFR4 inhibitors and agents capable of reducing bile acid levels and to the use thereof in the treatment of diseases.
    Type: Application
    Filed: July 22, 2020
    Publication date: January 28, 2021
    Inventors: Reimar Abraham, Mauricio Redondo-Müller
  • Combination of anti-FGFR4-antibody and bile acid sequestrant
    Patent number: 10765738
    Abstract: The present invention relates to the amelioration of toxic effects that are caused by therapies aimed at FGFR4-inhibition. In particular, the invention relates to the combination of FGFR4 inhibitors and agents capable of reducing bile acid levels and to the use thereof in the treatment of diseases.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 8, 2020
    Assignees: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Company Limited
    Inventors: Reimar Abraham, Mauricio Redondo-Müller
  • Anti-HER3 antibody-drug conjugate
    Patent number: 10383878
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: August 20, 2019
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore Hettmann, Reimar Abraham, Sabine Blum, Suguru Ueno
  • Human anti-FGFR4 antibody
    Patent number: 10358498
    Abstract: The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: July 23, 2019
    Assignees: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Company, Limited
    Inventors: Reimar Abraham, Keisuke Fukuchi, Tanja Lange, Johannes Bange, Ichiro Watanabe, Shinko Hayashi, Toshiaki Ohtsuka
  • ANTI-HER3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20190151328
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Application
    Filed: January 31, 2019
    Publication date: May 23, 2019
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore HETTMANN, Reimar ABRAHAM, Sabine BLUM, Suguru UENO
  • COMBINATION OF HUMAN ANTI-FGFR4 ANTIBODY AND SORAFENIB
    Publication number: 20190048088
    Abstract: The present invention relates to the medical use of antibodies against the FGF receptor 4 (FGFR4) combined with Sorafenib, in particular for the prevention or treatment of hyperproliferative diseases associated with FGFR expression, overexpression or hyperactivity.
    Type: Application
    Filed: February 9, 2017
    Publication date: February 14, 2019
    Inventors: Reimar Abraham, Keisuke Fukuchi
  • COMBINATION OF ANTI-FGFR4-ANTIBODY AND BILE ACID SEQUESTRANT
    Publication number: 20180133312
    Abstract: The present invention relates to the amelioration of toxic effects that are caused by therapies aimed at FGFR4-inhibition. In particular, the invention relates to the combination of FGFR4 inhibitors and agents capable of reducing bile acid levels and to the use thereof in the treatment of diseases.
    Type: Application
    Filed: May 18, 2016
    Publication date: May 17, 2018
    Inventors: Reimar Abraham, Mauricio Redondo-Müller
  • Human anti-FGFR4 antibody
    Publication number: 20170226213
    Abstract: The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.
    Type: Application
    Filed: August 11, 2015
    Publication date: August 10, 2017
    Inventors: Reimar Abraham, Keosile Fukuchi, Tanja Lange, Johannes Bange, Ichiro Watanabe, Shinko Hayashi, Toshiaki Ohtsuka
  • ANTI-HER3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20170021031
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Application
    Filed: October 4, 2016
    Publication date: January 26, 2017
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, U3 PHARMA GMBH
    Inventors: Thore HETTMANN, Reimar ABRAHAM, Sabine BLUM, Suguru UENO
  • COMBINATION THERAPY
    Publication number: 20100004193
    Abstract: A method of treating a subject affected by neoplastic diseases includes the administration to the subject of an aminoglycoside antibiotic in combination with a nucleoside analogue.
    Type: Application
    Filed: July 6, 2009
    Publication date: January 7, 2010
    Applicants: FONDAZIONE PER LA RICERCA BIOMEDICA AVANZATA ONLUS - ISTITUTO VENETO DI MEDICINA MOLECOLARE, UNIVERSITA' DEGLI STUDI DI PADOVA
    Inventors: Reimar ABRAHAM, Stefano SCHIAFFINO, Karla HAJMAN, Emanuele MINATTI
  • Method for identifying functional nucleic acids
    Publication number: 20040110177
    Abstract: The present invention relates to a method for identifying nucleic acid molecules functionally associated with a desired phenotype.
    Type: Application
    Filed: July 31, 2003
    Publication date: June 10, 2004
    Inventors: Axel Ullrich, Reimar Abraham